Rheumatoid Arthritis Flashcards
Process of RA development?
chronic inflammation –> growth of tissue (pannus) –> loss of bone and cartilage
RA triggers?
genetics
stochastic event
Consequences of inflammation?
loss of cartilage
formation of scar tissue
ligament laxity
tendon contractures
Gender more common for RA?
women 3:1
RA symptoms?
symmetrical joint pain and stiffness > 6 weeks
muscle pain
fatigue, weakness, low-grade fever, appetite decrease
joint tenderness and warmth ans swelling over affected joints
Rheumatoid nodule development
WHat joints is does RA usually start in
peripheral joints
Diagnosis for RA?
joint involvement
lab tests
- Rheumatoid factor in 60-70% pts
- elevated ESR and CRP
- anti-cyclic citrullinated pepide antibody
Duration of symptoms
When to start DMARDs?
within first 3 months of diagnosis
Non-pharm treatment?
Pts education
rest activity balance
reduce joint stress
diet
wt loss
surgery
occupational and physical therapy
Main DMARD used?
Methotrexate
MOA of Methotrexate?
anti-folate, less DNA synthesis, repair, cellular replication and immune response
Onset of methotrexate?
1-2 months
Methotrexate dosing?
7.5-25mg po weekly
Methotrexate common AE’s?
N & V
Fatigue
stomatisis
skin itch, burining, rash
hair loss
photosensitivity
Serious SE of methotrexate?
hepatotoxicity
hematologic abnormalities
pulmonary toxicity
reversible sterile in men
infection increase
Unique SE of hydroxchloroquine?
ocular toxicity?
DMARD drugs?
hydroxychloroquine
sulfasalazine
methotrexate
leflunomide
CI w/ methotrexate?
pregnancy/breastfeeding
severe hepatic impairment
caution in lung dysfunction
Current hematological abnormalities
DI w/ methotrexate?
TRIMETHOPRIM**
NSAIDs, PPI’s, Loops –> in doses 500-2000mg weekly
Monitoring DMARDs?
disease activity q 1-3m
radiographs q 6-12m
Saftey monitoring for methotrexate?
CBCs and LFTs
Creatinine
Initial chest x-ray
Which DMARD can replace methotrexate if not tolerated?
leflunomide